Association of <em>PIK3CA</em> mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma
Ugai, Tomotaka; Zhao, Melissa; Shimizu, Takashi; Akimoto, Naohiko; Shi, Shanshan; Takashima, Yasutoshi; Zhong, Rong; Lau, Mai Chan; Haruki, Koichiro; Arima, Kota; Fujiyoshi, Kenji; Langworthy, Benjamin; Masugi, Yohei; da Silva, Annacarolina; Nosho, Katsuhiko; Baba, Yoshifumi; Song, Mingyang; Chan, Andrew T.; Wang, Molin; Meyerhardt, Jeffrey A.; Giannakis, Marios; Väyrynen, Juha P.; Nowak, Jonathan A.; Ogino, Shuji (2021-08-02)
Ugai, T., Zhao, M., Shimizu, T., Akimoto, N., Shi, S., Takashima, Y., Zhong, R., Lau, M. C., Haruki, K., Arima, K., Fujiyoshi, K., Langworthy, B., Masugi, Y., da Silva, A., Nosho, K., Baba, Y., Song, M., Chan, A. T., Wang, M., … Ogino, S. (2021). Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma. OncoImmunology, 10(1), 1956173. https://doi.org/10.1080/2162402x.2021.1956173
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
https://creativecommons.org/licenses/by-nc/4.0/
https://urn.fi/URN:NBN:fi-fe2021090245034
Tiivistelmä
Abstract
Immunotherapy targeting the CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint axis has emerged as a promising treatment strategy for various cancers. Experimental evidence suggests that phosphatidylinositol-4,5-bisphosphonate 3-kinase (PI3K) signaling may upregulate CD274 expression. Thus, we hypothesized that PIK3CA mutation, PTEN loss, or their combined status might be associated with CD274 overexpression in colorectal carcinoma. We assessed tumor CD274 and PTEN expression by immunohistochemistry and assessed PIK3CA mutation by pyrosequencing in 753 patients among 4,465 incident rectal and colon cancer cases that had occurred in two U.S.-wide prospective cohort studies. To adjust for potential confounders and selection bias due to tissue availability, inverse probability weighted multivariable ordinal logistic regression analyses used the 4,465 cases and tumoral data including microsatellite instability, CpG island methylator phenotype, KRAS and BRAF mutations. PIK3CA mutation and loss of PTEN expression were detected in 111 of 753 cases (15%) and 342 of 585 cases (58%), respectively. Tumor CD274 expression was negative in 306 (41%), low in 195 (26%), and high in 252 (33%) of 753 cases. PTEN loss was associated with CD274 overexpression [multivariable odds ratio (OR) 1.83; 95% confidence interval (CI), 1.22–2.75; P = .004]. PIK3CA mutation was statistically-insignificantly (P = .036 with the stringent alpha level of 0.005) associated with CD274 overexpression (multivariable OR, 1.54; 95% CI, 1.03–2.31). PIK3CA-mutated PTEN-lost tumors (n = 33) showed higher prevalence of CD274-positivity (82%) than PIK3CA-wild-type PTEN-lost tumors (n = 204; 70% CD274-positivity) and PTEN-expressed tumors (n = 147; 50% CD274-positivity) (P = .003). Our findings support the role of PI3K signaling in the CD274/PDCD1 pathway.
Kokoelmat
- Avoin saatavuus [34589]
